GLPwatch

A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity

NCT05236517 · Completed

Last updated 2026-05-28

This study tests how taking 50 mg of semaglutide daily affects eating habits and stomach emptying in adults with obesity.

Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 60 people
Who can join Ages 18–65 · all sexes Healthy volunteers accepted.
Timeline Started 2022-02 · est. completion 2022-11
Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT05236517 ↗

Description as written by the study sponsor.

This study tests if semaglutide tablets of 50 mg can help people with obesity to lower their food intake compared to placebo. This study also tests how semaglutide 50 mg works on appetite, control of eating (such as cravings and restraints) and how long time the food stays in the stomach after a meal. In addition, how much semaglutide is in the blood will also be tested. Participants will either get semaglutide or placebo - which treatment participants will get is decided by chance. Participants will receive one semaglutide (or placebo) tablet per day during the 20-week treatment period. The dose of semaglutide is slowly increased every 4 weeks during the study to reach the treatment dose of 50 mg semaglutide taken for 4 weeks. The study lasts for up to 29 weeks for each person and includes a screening period (up to 4 weeks), a treatment period (20 weeks) and a follow-up period (total of 5 weeks after the last dosing). Participants will have 12 visits with the study doctors at the institute.

Treatments tested

Main thing measuredRelative change in energy intake during ad libitum lunch
SponsorNovo Nordisk A/S
Conditions studiedObesity
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05236517 ↗